Tourmaline Bio Inc. to Present Topline Results from Phase 2 TRANQUILITY Trial

NEW YORK, May 19, 2025 — Tourmaline Bio, Inc. (NASDAQ: TRML), a biotechnology company specializing in transformative medicines for immune and inflammatory diseases, announced it will present the topline results from its ongoing Phase 2 TRANQUILITY trial on May 20, 2025. The trial evaluates the efficacy of pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease.

The company will host a conference call and webcast beginning at 8:30 a.m. ET to discuss the trial’s findings. Tourmaline’s management team will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Bhatt also serves as the Chair of Tourmaline’s Cardiovascular Scientific Advisory Board.

Tourmaline Bio, Inc., based in New York, focuses on developing medicines to improve patient outcomes in life-altering immune diseases. The company’s stock is traded on the Nasdaq, with a close price of $16.56 as of May 15, 2025. The market capitalization stands at approximately $398.69 million. Despite a negative price-to-earnings ratio of -5.14, the company has shown resilience with a 52-week high of $29.7883 and a low of $11.56.

For those interested in attending the event, registration details can be found on Tourmaline’s website under the “Events and Presentations” section. This presentation is expected to provide significant insights into the potential of pacibekitug as a treatment option for patients with chronic kidney disease and elevated inflammatory markers.